Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by Stifel Nicolaus
Stifel Nicolaus lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Thursday, The Fly reports. Stifel Nicolaus currently has $23.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $55.00.
Several other research analysts have also commented on the company. ValuEngine lowered Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday. TheStreet lowered Supernus Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, August 29th. BidaskClub raised Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, November 5th. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. Supernus Pharmaceuticals has an average rating of Hold and a consensus price target of $46.50.
Supernus Pharmaceuticals stock traded up $0.57 during midday trading on Thursday, reaching $21.72. 1,010,300 shares of the stock traded hands, compared to its average volume of 579,923. The firm has a market cap of $1.53 billion, a PE ratio of 10.60, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. Supernus Pharmaceuticals has a 12-month low of $19.35 and a 12-month high of $49.25. The company has a 50-day simple moving average of $26.80 and a two-hundred day simple moving average of $30.29. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70.
In related news, CEO Jack A. Khattar bought 7,200 shares of the stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $26.39 per share, for a total transaction of $190,008.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.57% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Capital Management Corp VA grew its stake in shares of Supernus Pharmaceuticals by 10.7% in the 2nd quarter. Capital Management Corp VA now owns 190,290 shares of the specialty pharmaceutical company’s stock valued at $6,297,000 after purchasing an additional 18,420 shares during the last quarter. Creative Planning boosted its stake in shares of Supernus Pharmaceuticals by 28.3% in the second quarter. Creative Planning now owns 17,228 shares of the specialty pharmaceutical company’s stock valued at $570,000 after buying an additional 3,802 shares in the last quarter. Point72 Hong Kong Ltd boosted its stake in shares of Supernus Pharmaceuticals by 324.1% in the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $548,000. Finally, Provident Investment Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 13.8% in the second quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock valued at $24,034,000 after buying an additional 88,099 shares in the last quarter. Institutional investors own 99.14% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Story: Systematic Risk
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.